The totality of the evidence suggests that FGF-23 does not have a direct causal role in the development of cardiovascular diseases, and directly targeting FGF-23 is therefore unlikely to represent a clinically meaningful modifiable target to prevent cardiovascular disease. Here, FGF23 is linked to cardiovascular disorder.